@SGVaccineInjuries on Telegram

[theblackhole]

the whole conspiracy runs out of control
humans are the worst animals on earth
most evil
most diabolical
most destructive
human will destine to suffer
because of their evil minds and evil deeds
covid is just the tip of the iceberg

 

[capamerica]

The risk of catching Wuhan is lower than the risk posed by the vaccine because there are zero community cases at the moment. However if community transmission starts trending upward the risk assessment will be reviewed and revised if necessary.

Wrong. Again. Call it 0 for 184 tries.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01018-7/fulltext

COVID-19 vaccine impact in Israel and a way out of the pandemic

• Eyal Leshem

In December, 2020, Israel initiated a national campaign to vaccinate its population with Pfizer–BioNTech's mRNA COVID-19 vaccine BNT162b2 (tozinameran). Israel's Ministry of Health recommended a two-dose schedule with a 21-day interval between doses. Israel delivered more than 10 million doses within 4 months; by April 19, 2021, 54% of the entire population of 9·1 million people, and 88% of people aged 50 years or older, had received two doses.
1
Factors contributing to Israel's rapid roll-out include its small geographical and population sizes; advanced information technology that allowed prioritisation, allocation, and documentation of vaccines for eligible individuals; effective cooperation between government and community-based health funds, which were charged with providing vaccines to those they insured; and experience in rapid large-scale emergency responses.
2
Vaccines were rolled out around the time of Israel's third and largest wave of SARS-CoV-2 infections, with a peak 7-day moving average of 8328 new infections per day, which resulted in a 2-month national lockdown. Thus, Israel's setting provided a robust platform on which to examine vaccine effectiveness and the impact of high vaccine coverage in real-life conditions at a national level. From March, 2021, onwards, Israel reported a rapid decline in COVID-19 cases across all age groups, despite the easing of lockdown restrictions and reopening of education and commerce. By April 19, 2021, the 7-day moving average of new cases dropped to 149 per day, indicating effective control of the pandemic within the country's borders.
1
,
3
The marked reduction in new cases prompted the Israeli Government to ease nationwide restrictions, including the discontinuation of face covering use in open spaces.
• View related content for this article
In The Lancet, Eric Haas and colleagues report on a nationwide observational study of the impact and vaccine effectiveness of BNT162b2 in Israel.
3
Israel's Ministry of Health used aggregated data from the national SARS-CoV-2 surveillance and vaccination programme dataset to compare infection and disease incidence between vaccinated and unvaccinated people. Overall, of 232 268 SARS-CoV-2 infections during the study period (Jan 24 to April 3, 2021), 154 648 (66·6%) occurred in people aged 16 years or older and were included in the analyses (of which 20·4% were in the Arab sector, 15·7% in the ultra-Orthodox sector, and 63·9% in the general Jewish [non-ultra-Orthodox] sector). Adjusted estimates of vaccine effectiveness at 7 days or longer after the second dose were 95·3% (95% CI 94·9–95·7) against SARS-CoV-2 infection, 91·5% (90·7–92·2) against asymptomatic SARS-CoV-2 infection, 97·0% (96·7–97·2) against symptomatic SARS-CoV-2 infection, 97·2% (96·8–97·5) against COVID-19-related hospitalisation, 97·5% (97·1–97·8) against severe or critical COVID-19-related hospitalisation, and 96·7% (96·0–97·3) against COVID-19-related death. Vaccine effectiveness against symptomatic SARS-CoV-2 infection, COVID-19-related hospitalisation, and COVID-19-related death exceeded 96% across all age groups, including older adults (aged ≥75 years and ≥85 years). These results closely mirror the efficacy estimates of the BNT162b2 vaccine reported in the phase 3 trial.
4
The strengths of the study include its nationwide design, mandatory routine reporting of new infections and of vaccination status to the national dataset, large sample size, exclusive use of BNT162b2, and occurrence of a highly efficient vaccine roll-out during peak transmission of SARS-CoV-2, which resulted in high vaccination coverage of most of the adult population. However, several limitations should be considered when interpreting the results. First, social desirability bias affecting symptom questionnaire respondents and presymptomatic infections at the time of questioning could have contributed to an overestimation of vaccine effectiveness against asymptomatic infection. Additionally, patients with COVID-19 who reported symptoms were defined as asymptomatic if they did not report fever or respiratory symptoms. This unorthodox case definition might have resulted in a substantial overestimation of vaccine effectiveness against asymptomatic SARS-CoV-2 infection.
5
Second, during early 2021, the B.1.1.7 variant of SARS-CoV-2 was estimated to account for 95% of cases in Israel, and the results thus indicate that the vaccine was effective against this variant of concern. However, the study did not report on effectiveness against other variants of concern, such as B.1.351 and P.1. Concerns regarding breakthrough infections were recently raised as a case-cohort study from Israel reported a disproportionally high infection rate with the B.1.351 variant in fully vaccinated compared with unvaccinated individuals.
6
Nevertheless, the incidence of B.1.351 infection in Israel to date remains low. Rapid mass vaccination coupled with non-pharmaceutical interventions
7
might have successfully controlled its spread.
Haas and colleagues' findings from Israel suggest that high vaccine coverage rates could offer a way out of the pandemic.
5
,
8
Regrettably, rapid population level coverage cannot be easily replicated in many other countries. The global use of the BNT162b2 vaccine is limited by supply issues, high costs, and ultra-cold chain storage requirements. Global COVID-19 vaccine roll-out has been sluggish, and vaccine distribution is inequitable despite the achievements of COVAX, mainly due to the lack of adequate manufacturing scalability.
9
,
10
Rapid expansion of deployment of other effective vaccines with more achievable cold chain storage requirements remains an urgent global priority.
9
Facing such challenges, alternative approaches must be considered to allow rapid protection of at-risk populations against severe COVID-19. One such approach is deferring the second dose to accelerate and maximise coverage of the first dose in the population. Indeed, the situation in Scotland looks promising: the first dose of BNT162b2 was associated with a vaccine effectiveness of 91% (85–94) for COVID-19-related hospitalisation at 28–34 days post-vaccination.
11
Israel's robust dataset could allow further assessment and corroboration of first-dose short-term effectiveness and lead other countries to considering deferring the second vaccine dose.
3
Post-introduction vaccine effectiveness studies such as those from Israel
3
and the UK
5
,
11
will gain increasing importance in augmenting the current evidence, which has so far been based only on data from phase 3 efficacy trials. WHO has published a best practice guidance document on how to conduct vaccine effectiveness assessments using observational study designs.
12
Israel's experience provides impetus for countries to proactively pursue high vaccine coverage to protect the population;
8
however, rollout would need to follow the WHO prioritisation roadmap to maximise the public health impact, in light of vaccine supply constraints. More post-introduction vaccine effectiveness studies will be required. Timely reporting of vaccine effectiveness against variants of concern, the duration of protection across age groups and geographical settings, and the effectiveness of alternative dosing regimens is crucial to provide data-driven immunisation policies.
12

 

[micromachine]

cap you a lover of jews?

 

[Hypocrite-The]

Only 30 who experience serious side effects of COVID-19 vaccines qualified for financial assistance, out of 104 applications: Minister Gan Kim Yong - The Online Citizen Asia
About 104 residents who experienced serious side effects related to COVID-19 vaccines have applied for financial assistance, but only 30 applications were qualified for compensation, said Health Minister Gan Kim Yong in Parliament on Tuesday (11 May).
Of the 30 applications, 21 were related to hypersensitivity or allergic reactions, four neurology-related cases, three cardiology-related cases, and one case related to haematology and dermatology each.
Mr Gan noted that 75 applications have been evaluated, 45 were rejected and the remaining 29 applications are still pending.
The Workers’ Party (WP) Member of Parliament (MP) for Aljunied GRC Sylvia Lim posed a supplementary question to ask the Minister to clarify why the 45 applications were rejected.
In response to Ms Lim, Mr Gan said the applications were assessed by the panels based on “a balance of probability” and whether they are “more likely to be associated” with vaccination.
He explained that the 45 applications were not qualified as the severity did not meet the level of severe reactions required.
“Some of it may be rashes, maybe some swelling but does not require extensive medical care and therefore may not qualify for the application.
“So I think there are a variety of reasons so it suffices to say that they are all assessed thoroughly by the independent panel before they were approved or rejected,” said the Minister.
In his Parliamentary speech, Mr Gan revealed that the Health Sciences Authority (HSA) has received about 2,796 suspected adverse event reports associated with the use of COVID-19 vaccines as of 18 April 2021.
These represent 0.13 per cent of the doses administered, but Mr Gan claimed the majority of the reports are “non-serious adverse events”.
“Only 0.004 per cent of our doses administered have reported serious adverse events. In general, the observed trend of adverse events within Singapore is consistent with those reported overseas,” he said.
According to Mr Gan, the most commonly reported adverse events include symptoms like dizziness, fever, muscle ache, pain at the injection site, headache and allergic reactions.
“These symptoms generally resolve within a few days. Most of the patients here have recovered or are recovering from these adverse events,” he added.
Mr Gan further clarified that Singapore has not seen “any local cases of unusual blood clots associated with low platelets” that have been reported with other vaccines used overseas, adding that the HSA has also released the details of reported adverse events on 6 May 2021.
“HSA continues to actively monitor and review the safety of the COVID-19 vaccines. In addition to monitoring reports from international regulatory counterparts, HSA also reviews reports from local healthcare practitioners on adverse events following vaccination regardless of whether causality can be established.
“HSA has appointed three expert panels to review neurological, cardiac and hypersensitivity adverse events, such as anaphylaxis, which occur following vaccination. This will allow for prompt and appropriate actions to safeguard public health and enhance vaccination safety,” he said.
Share this:

 

[chickenpieforeveryone]

maybe batman

What if you ended up like spiderman after getting the vaccine?

 

[kaninabuchaojibye]

Only 30 who experience serious side effects of COVID-19 vaccines qualified for financial assistance, out of 104 applications: Minister Gan Kim Yong - The Online Citizen Asia
About 104 residents who experienced serious side effects related to COVID-19 vaccines have applied for financial assistance, but only 30 applications were qualified for compensation, said Health Minister Gan Kim Yong in Parliament on Tuesday (11 May).
Of the 30 applications, 21 were related to hypersensitivity or allergic reactions, four neurology-related cases, three cardiology-related cases, and one case related to haematology and dermatology each.
Mr Gan noted that 75 applications have been evaluated, 45 were rejected and the remaining 29 applications are still pending.
The Workers’ Party (WP) Member of Parliament (MP) for Aljunied GRC Sylvia Lim posed a supplementary question to ask the Minister to clarify why the 45 applications were rejected.
In response to Ms Lim, Mr Gan said the applications were assessed by the panels based on “a balance of probability” and whether they are “more likely to be associated” with vaccination.
He explained that the 45 applications were not qualified as the severity did not meet the level of severe reactions required.
“Some of it may be rashes, maybe some swelling but does not require extensive medical care and therefore may not qualify for the application.
“So I think there are a variety of reasons so it suffices to say that they are all assessed thoroughly by the independent panel before they were approved or rejected,” said the Minister.
In his Parliamentary speech, Mr Gan revealed that the Health Sciences Authority (HSA) has received about 2,796 suspected adverse event reports associated with the use of COVID-19 vaccines as of 18 April 2021.
These represent 0.13 per cent of the doses administered, but Mr Gan claimed the majority of the reports are “non-serious adverse events”.
“Only 0.004 per cent of our doses administered have reported serious adverse events. In general, the observed trend of adverse events within Singapore is consistent with those reported overseas,” he said.
According to Mr Gan, the most commonly reported adverse events include symptoms like dizziness, fever, muscle ache, pain at the injection site, headache and allergic reactions.
“These symptoms generally resolve within a few days. Most of the patients here have recovered or are recovering from these adverse events,” he added.
Mr Gan further clarified that Singapore has not seen “any local cases of unusual blood clots associated with low platelets” that have been reported with other vaccines used overseas, adding that the HSA has also released the details of reported adverse events on 6 May 2021.
“HSA continues to actively monitor and review the safety of the COVID-19 vaccines. In addition to monitoring reports from international regulatory counterparts, HSA also reviews reports from local healthcare practitioners on adverse events following vaccination regardless of whether causality can be established.
“HSA has appointed three expert panels to review neurological, cardiac and hypersensitivity adverse events, such as anaphylaxis, which occur following vaccination. This will allow for prompt and appropriate actions to safeguard public health and enhance vaccination safety,” he said.
Share this:

it's strange that they cannot tell you such info until and unless a question is asked in parliament

such info should be published everyday if they want the public to have more trust in their management of this covid pandemic